Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark Cameron is active.

Publication


Featured researches published by Mark Cameron.


Journal of Organic Chemistry | 2011

A Practical Synthesis of Renin Inhibitor MK-1597 (ACT-178882) via Catalytic Enantioselective Hydrogenation and Epimerization of Piperidine Intermediate

Carmela Molinaro; Scott Shultz; Amélie Roy; Stephen Lau; Thao Trinh; Remy Angelaud; Paul D. O’Shea; Stefan Abele; Mark Cameron; Ed Corley; Jacques-Alexis Funel; Dietrich Steinhuebel; Mark Weisel; Shane W. Krska

A practical enantioselective synthesis of renin inhibitor MK-1597 (ACT-178882), a potential new treatment for hypertension, is described. The synthetic route provided MK-1597 in nine steps and 29% overall yield from commercially available p-cresol (7). The key features of this sequence include a catalytic asymmetric hydrogenation of a tetrasubstituted ene-ester, a highly efficient epimerization/saponification sequence of 4 which sets both stereocenters of the molecule, and a short synthesis of amine fragment 2.


Journal of Pharmaceutical and Biomedical Analysis | 2002

Employment of on-line FT-IR spectroscopy to monitor the deprotection of a 9-fluorenylmethyl protected carboxylic acid peptide conjugate of doxorubicin

Mark Cameron; George X. Zhou; Micheal B Hicks; Vincent Antonucci; Zhihong Ge; David R. Lieberman; Joesph E Lynch; Yao-Jun Shi

A method for accurately determining the end-point, >98% conversion, of the deprotection reaction of a highly toxic 9-fluorenylmethyl (Fm) ester 1b to its corresponding carboxylate 1d in real time by FT-IR spectroscopy is reported. Advantages of this method over analysis by conventional chromatographic means include real time determination of the end-point of a reaction that is time sensitive to by-product formation, and elimination of sampling a highly toxic reaction mixture. The FT-IR method is based on monitoring, in real time, the disappearance of the Fm ester carbonyl band for 1b at 1737 cm(-1), during deprotection by piperidine, and calibration models were established by Partial Least Squares (PLS) regression analysis with high performance liquid chromatography (HPLC) as reference. The best calibration model was built with 5 PLS factors in the spectral range of 1780-1730 and 1551-1441 cm(-1) and resulted in a standard error of cross validation (SECV) of 0.63 mM 1b and a standard error of prediction (SEP) of 0.51 mM 1b in the range of 0-25 mM. This error of prediction is approximately 0.8% of the initial concentration of 1b and is well within our specifications of <2% initial concentration.


Applied Catalysis A-general | 2000

The unexpected formation of N-benzylated tertiary amines from their corresponding CBZ-protected precursors

Mark Cameron; Robert Darrin Wilson

The unexpected formation of N-benzyl tertiary amines was observed during the hydrogenolysis of their corresponding CBZ-protected secondary amines, indicating a potential problem for the industrial application of a process otherwise thought to be robust. The reaction is favoured by low hydrogen availability, and under such conditions competitive formation of N-benzyl analogues occurs rather than affording exclusively the expected free amine.


Synthesis | 1996

A Convenient Method for the Preparation of 5-, 6- and 7-Azaindoles and Their Derivatives

David Hands; Brian Bishop; Mark Cameron; John S. Edwards; Ian F. Cottrell; Stanley H. B. Wright


Organic Process Research & Development | 2006

The Expedient Synthesis of 4,2‘-Difluoro-5‘-(7-trifluoromethyl- imidazo[1,2-a]pyrimidin-3-yl)biphenyl-2-carbonitrile, a GABA α2/3 Agonist

Mark Cameron; Bruce S. Foster; Joseph E. Lynch; Yao-Jun Shi; Ulf-H. Dolling


Archive | 1996

Chemical synthesis of azaindoles

Brian Cchristopher Bishop; Ian F. Cottrell; Mark Cameron; David Hands


Journal of Organic Chemistry | 2002

Efficient One-Pot Synthesis of the 2-Aminocarbonylpyrrolidin-4-ylthio-Containing Side Chain of the New Broad-Spectrum Carbapenem Antibiotic Ertapenem

Karel M. J. Brands; Ronald B. Jobson; Karen M. Conrad; J. Michael Williams; Brenda Pipik; Mark Cameron; Antony J. Davies; Peter G. Houghton; Michael S. Ashwood; Ian F. Cottrell; Robert A. Reamer; Derek J. Kennedy; Ulf-H. Dolling; Paul J. Reider


Archive | 2010

Novel cationic lipids with short lipid chains for oligonucleotide delivery

Mark Cameron; Jennifer R. Davis; Weimin Wang


Organic Process Research & Development | 2012

Convergent, Fit-For-Purpose, Kilogram-Scale Synthesis of a 5-Lipoxygenase Inhibitor

Stéphane G. Ouellet; Danny Gauvreau; Mark Cameron; Sarah J. Dolman; Louis-Charles Campeau; Gregory Hughes; Paul D. O’Shea; Ian W. Davies


Archive | 2000

Salt form of a conjugate useful in the treatment of prostate cancer

Shyam B. Karki; Mark Cameron; David R. Lieberman; Joseph E. Lynch; Michael A. Robbins; Yao-Jun Shi; Örn Almarsson; Michael J. Kaufman; Maneesh J. Nerurkar

Collaboration


Dive into the Mark Cameron's collaboration.

Researchain Logo
Decentralizing Knowledge